Mastoparan (MP) peptides, distributed in insect venoms, induce a local inflammatory response post envenomation. Most endogenous MPs share common structural elements within a tetradecapeptide sequence that adopts an amphipathic helix whilst traversing biological membranes and when bound to an intracellular protein target. Rational modifications to increase cationic charge density and amphipathic helicity engineered mitoparan (MitP), a mitochondriotoxic bioportide and potent secretagogue. Following intracellular translocation, MitP is accreted by mitochondria thus indicating additional utility as an antimicrobial agent. Hence, the objectives of this study were to compare the antimicrobial activities of a structurally diverse set of cationic cell penetrating peptides, including both MP and MitP sequences, and to chemically engineer analogues of MitP for potential therapeutic applications. Herein, we confirm that, like MP, MitP is a privileged structure for the development of antimicrobial peptides active against both prokaryotic and eukaryotic pathogens. Collectively, MitP and target-selective chimeric analogues are broad spectrum antibiotics, with the Gram-negative A. baumannii demonstrating particular susceptibility. Modifications of MitP by amino acid substitution at position-14 produced peptides, Δ14MitP analogues, with unique pharmacodynamic properties. One example, [Ser 14 ]MitP, lacks both cytotoxicity against human cell lines and mast cell secretory activity yet retains selective activity against the encapsulated yeast C. neoformans.
Introduction
Animal venoms usually comprise a complex mixture of peptide toxins that act potently and rapidly when envenomated into soft tissues [1] . Such venoms are, therefore, a remarkable resource for the discovery of bioactive peptides highly active against every generic class of protein drug target. Approximately 50% of the venom of the Korean leather-jacket Vespula lewisii consists of the peptide mastoparan (MP; INLKALAALAKKIL), named to signify its capacity to activate mast cell secretion by a receptor-independent mechanism [2] . Moreover, as described herein, MP is not a peptide species but rather a genus of structurally related tetradecapeptides from hymenopteran venoms which induce receptor-independent mast cell degranulation to promote pain and other local inflammatory responses [3] .
The term privileged scaffold was introduced by Evans et al. [4] to serve as a general descriptor of a molecular framework or architecture that can be readily modified to produce ligands for distinct receptors. This original study focussed upon the advantages of the benzodiazepine nucleus that seemingly resulted from the molecular mimicry of a beta turn. However, since this time a variety of other privileged structures and scaffolds have been identified and exploited [5] of which examples pertinent to this study include peptides, peptoids, cyclic peptides and a variety of conformation-constrained structural mimetics [6, 7] . There are several structural motifs almost invariably maintained by all endogenous MPs. Ile always occupies the amino terminus of endogenous peptides. Enzymatic cleavage of Ile 1 by enzymes in human serum is relatively slow, but the resulting tridecapeptide, NLKALAALAKKIL, has much reduced activity against Gram-negative Acinetobacter baumannii compared with MP [8] . The MP tetradecapeptides are cationic in nature, positive charges being contributed mostly by the ε-amino function of multiple Lys residues. Leucinamide usually occupies the carboxyl-terminal of endogenous MP analogues and loss of the amide function is detrimental to biological activities including erythrocyte lysis and mast cell degranulation [9, 10] . The formation of an amphipathic alpha helix is also a major determinant of the many activities of MP peptides. The structure of MP is disordered in aqueous solution but becomes helical in the presence of lipids and membrane mimetics [11, 12] . MP is also helical when bound to a primary intracellular protein target, namely pertussis toxin-sensitive heterotrimeric G proteins [13, 14] . As reviewed elsewhere [15, 16] , the privileged nature of MP peptides enables them to influence the activities of many additional protein targets that include Ca 2+ -ATPases [17] , calmodulin [18] and glycogen phosphorylase [19] .
The capacity of MP peptides to translocate cell membranes as an amphipathic helix facilitates the presentation of a cationic hydrophilic face on the inner side of the plasma membrane. This in turn mimics some structural determinants of activated G protein-coupled receptors [3, [20] [21] [22] . Hence, the design of mitoparan (MitP; [Lys 5, 8 , Aib 10 ]MP; Aib = 2-aminoisobutyric acid) was dictated by the strategy of substituting additional cationic charge into the hydrophilic face of MP [23] . The substitution of Ala 10 with Aib, a known helix promoter [24, 25] , was intended to both increase the propensity for helix formation and also confer resistance to proteases. The design of MitP deliberately included Ile 1 and leucinamide 14 to maintain some structural determinants of the privileged scaffold of MP. When directly compared with MP [23] , MitP is a more potent secretagogue of ß-hexosaminidase, a secretory granule marker, from RBL-2H3 mast cells and displays enhanced cytotoxicity when exogenously added to U373MG astrocytoma cells. Of specific relevance to this study, MitP and chimeric analogues, N-terminally extended with additional homing motifs, are specifically accreted by mitochondria following their efficient cellular translocation into eukaryotic cells [26, 27] . Moreover, MitP promotes apoptosis through mechanisms that include the increased phosphorylation of mitogen-activated protein kinases and the release of cytochrome c from mitochondria [23, 26] . The latter response is mediated, at least in part, by the modulation of voltage-dependent ion channels (VDAC) expressed in mitochondrial membranes [26] . As further described herein, endogenous MP analogues are reported to display a wide range of antibiotic activities. Thus, we reasoned that MitP, a peptide that specifically accretes within mitochondria, could be further engineered as an antibacterial agent. Accepting the endosymbiotic origin of the eukaryotic mitochondrion [28] , we considered it likely that MitP analogues could also interact with both the lipid and protein constituents of prokaryotic cell membranes. However, it is obvious that the clinical utility of any antibiotic peptide that simultaneously promotes mast cell degranulation and/or eukaryotic cell death would be severely compromised. Thus, the major objective of this study was to identify MitP analogues with more desirable and selective antibiotic properties. When modelled as a classic α-helix, the highly conserved aliphatic side chain of leucinamide 14 clearly contributes to the hydrophobic face of endogenous MP sequences. Our approach to this problem was to subtly perturb the privileged structure of MitP through the selective modification of the carboxyl terminal. Our findings provide powerful evidence that minor changes to the privileged structure of MitP can indeed be employed to engineer selective antibacterial and antifungal agents.
Materials and methods

Materials
Fluorenylmethyloxycarbonyl (Fmoc)-protected amino acids for microwave-assisted peptide synthesis were purchased from Novabiochem (Beeston, UK). AGTC Bioproducts Ltd (Hessle, UK) supplied dimethylformamide, dichloromethane and piperidine for solid phase peptide synthesis. Mammalian culture medium and supplements were purchased from Sigma-Aldrich (Poole, UK). Microbial assay plates were purchased from Corning (Australia). Bacterial growth medium was purchased from Bacto Laboratories (Mount Ptitchard, NSW, Australia) and fungal growth medium and culture agar from Becton Dickinson (North Ryde, NSW, Australia). Unless otherwise indicated all other research grade chemicals were purchased from Sigma-Aldrich (Poole, UK or Castle Hill, NSW, Australia).
Microwave-assisted solid phase peptide synthesis
Solid phase peptide syntheses were performed using a Discover SPS Microwave Peptide Synthsizer (CEM Microwave Technology Ltd, Buckingham, UK) with fibre optic temperature control [29] . Peptides were synthesized (0.1 mmol scale) using Rink amide MBHA resins preloaded with the first amino acid (AnaSpec, Inc. Cambridge Bioscience Ltd, Cambridge, UK) and employed an N-α-Fmoc protection strategy with O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU; AGTC Bioporoducts) activation. Deprotection with 7 ml of 20% piperidine was performed for 3 min at 50 W/ 75°C. A majority of AA coupling reactions were accomplished with a 4-fold molar excess of Fmoc-protected AA with HCTU and diisopropylethylamine (DIPEA), molar ratio of 1:1:2 (AA/HCTU/DIPEA), in 4 ml for 10 min at 25 W/75°C. Arg coupling was performed in two stages: 30 min 0 W/∼25°C followed by 5 min at 17 W/75°C. To reduce racemization of Cys and His, coupling conditions were 5 min at 0 W/∼25°C followed by 6 min at 17 W/50°C with the hindered base collidine (TMP) at molar ratio of 1:1:2 (AA/HCTU/TMP) [30] . Aspartimide formation was reduced by the substitution of piperidine with 5% piperazine and 0.1 M 1-hydroxybenztriazole hydrate (HOBt) in the deprotection solution [30] .
Fluorescent peptides to be used in confocal live cell imaging were synthesised by amino-terminal acylation with the single isomer 6-carboxy-tetramethylrhodamine (TAMRA; Novabiochem, Beeston, UK).
All peptides were purified to apparent homogeneity by semi-preparative scale high performance liquid chromatography and lyophilised. As reported herein (Table 2) , the predicted masses of novel MitP analogues described in this study (average M+H + ) were confirmed by matrix-assisted laser desorption ionization (MALDI) time of flight mass spectrometry operated in positive ion mode [26] .
Mammalian cell culture
Rat basophilic leukaemia cells (RBL-2H3) are widely employed as an accepted mucosal mast cell model for the investigation of regulated secretory phenomenon and were therefore used to evaluate the secretory effects of MitP analogues [29, 31, 32] . RBL-2H3 were maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing L-glutamine (0.1 mg/ml) supplemented with foetal bovine serum 10% (v/v), penicillin (100 U/ml) and streptomycin (100 μg/ml) in a humidified atmosphere of 5% CO 2 at 37°C. U373MG human astrocytoma cells are an extensively-characterised and routinely-used cellular model within our laboratory for the investigation of peptide-induced cytotoxic events [26, 31, 33] and were therefore used to determine the cytotoxicity profiles of MitP analogues. HEK293 cells were additionally utilised for cytotoxic screening. Both U373MG and HEK293 were maintained in DMEM as above.
Secretory efficacies of MP and MitP analogues
To determine the secretory efficacies of polybasic peptides, the exocytosis of β-hexosaminidase, a secretory lysosomal marker, was determined in RBL-2H3 cells as previously described [29, [34] [35] [36] . ß-Hexosaminidase was assayed in samples of cell medium following exogenous application of peptides to RBL-2H3 cells in HAMS F12 medium. 5 μl Aliquots of medium were transferred into 96 well plates and incubated with ρ-nitrophenyl-N-acetyl-ß-D-glucosamide (20 μl of 1 mM in 0.1 M sodium citrate buffer, pH 4.5) for 1 h at 37°C. Na 2 CO 3 / NaHCO 3 buffer (200 μl of 0.1 M, pH 10.5) was then added and ß-hexosaminidase activity determined by colourimetric analysis at 405 nm.
Eukaryotic cytotoxicity assays
Peptide-induced changes in cellular viability were quantitatively assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) conversion assay [26, 37] . U373MG cells were cultured as above in 96 well plates, treated with peptides for 4 h at 37°C, and further incubated with MTT (0.5 g/L) for 3 h at 37°C. The insoluble formazan product was solubilised with DMSO and MTT conversion determined by colorimetric analysis at 540 nm. Cellular viability was expressed as a percentage of those cells treated with vehicle (medium) alone. Graphical representations of changes in cell viability were calculated using GraphPad Prism 7 software.
Peptide-induced changes in eukaryotic cell viability were also performed by the CO-ADD (Community for Antimicrobial Drug Discovery) and used HEK293 cells. Cells were counted manually in a Neubauer haemocytometer and then plated in 384-well plates containing peptides to give a density of 6000 cells/well in a final volume of 50 μL and incubated for 20 h at 37°C in 5% CO 2 . Cytotoxicity was measured by fluorescence, Ex: 560/10 nm, Em: 590/10 nm (F 560/590 ), after addition of 5 μL of 25 mg/L Resazurin (2.3 mg/L final concentration) and after incubation for a further 3 h at 37°C in 5% CO 2 . The fluorescence intensity was measured using a Tecan M1000 Pro monochromator plate reader, using the automatic gain calculation. CC 50 
Identification and characterisation of antimicrobial peptides
All antimicrobial assays detailed below were performed by CO-ADD funded by the Wellcome Trust (UK) and The University of Queensland (Australia).
Primary antimicrobial screening
To select cationic membrane translocating peptides for further analyses, whole cell growth inhibition assays were performed at a single concentration of 32 mg/L, in duplicate (n = 2). These assays included 5 bacterial pathogens: Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus, and 2 fungi: Candida albicans and Cryptococcus neoformans. Assays were performed as below.
The significance of the inhibition values was determined by modified Z-scores, calculated using the median and MAD of the samples (no controls) on the same plate. Samples with inhibition value above 80% and Z-Score above 2.5 for either replicate (n = 2 on different plates) were deemed as active. Candidate active antimicrobial peptides were further assayed to ascertain MIC values as described below.
Sample preparation
Peptides were prepared to a 10 mg/mL stock in water and stored at −20°C. Peptides were further prepared in water to 32 mg/L and serially diluted 1:2 fold, 8 times. Each sample concentration was prepared in 384-well plates, non-binding surface plate (Corning 3640) for each bacterial/fungal strain and performed in triplicate (n = 3). All the sample preparation was performed using liquid handling robots.
Antibacterial assays
All bacteria were cultured in Cation-adjusted Mueller Hinton broth at 37°C overnight. A sample of each culture was then diluted 40-fold in fresh broth and incubated at 37°C for 1.5-3 h. The resultant mid-log phase cultures were diluted (CFU/mL measured by OD 600 ), then added to each well of the compound containing plates, giving a cell density of 5 × 10 5 CFU/mL and a total volume of 50 μL. All the plates were covered and incubated at 37°C for 18 h without shaking. Inhibition of bacterial growth was determined measuring absorbance at 600 nm (OD 600 ), using a Tecan M1000 Pro monochromator plate reader. The percentage of growth inhibition was calculated for each well, using the negative control (medium only) and positive control (bacteria without inhibitors) on the same plate as references. The MIC was determined as the lowest concentration at which the growth was fully inhibited, defined by an inhibition ≥80%. In addition, the maximal percentage of growth inhibition is reported as DMax, indicating any compounds with partial activity. Hits were classified by MIC ≤ 16 mg/L.
Antifungal assays
Fungi strains were cultured for 3 days on Yeast Extract-Peptone Dextrose agar at 30°C. A suspension of 1 × 10 6 -5 × 10 6 CFU/mL (as determined by OD 530 ) was prepared from five colonies. The suspension was subsequently diluted and added to each well of the compoundcontaining plates giving a final cell density of fungi suspension of 2.5 × 10 3 CFU/mL and a total volume of 50 μL. All plates were covered and incubated at 35°C for 36 h without shaking. Growth inhibition of C. albicans was determined measuring absorbance at 530 nm (OD 530 ), while the growth inhibition of C. neoformans was determined measuring the difference in absorbance between 600 and 570 nm (OD 600-570 ), after the addition of resazurin (0.001% final concentration) and incubation at 35°C for an additional 2 h period. The absorbance was measured using a Biotek Synergy HTX plate reader. In both cases, the percentage of growth inhibition was calculated for each well, using the negative control (medium only) and positive control (fungi without inhibitors) on the same plate. The MIC was determined as the lowest concentration at which the growth was fully inhibited, defined by an inhibition ≥80% for C. albicans and an inhibition ≥70% for C. neoformans. Due to a higher variance in growth and inhibition, a lower threshold was applied to the data for C. neoformans. In addition, the maximal percentage of growth inhibition is reported as DMax, indicating any compounds with marginal activity. Hits were classified by MIC ≤ 16 mg/L.
Antibiotic standards, preparation and quality control (QC)
Colistin and Vancomycin were used as positive bacterial inhibitor standards for Gram-negative and Gram-positive bacteria, respectively. Fluconazole was used as a positive fungal inhibitor standard for C. albicans and C. neoformans. Tamoxifen was used as a positive cytotoxicity standard. Antibiotics were used at 4 concentrations, with 2 above and 2 below its MIC or CC 50 value.
The QC of the assays was determined by the Z'-Factor, calculated from the negative (medium only) and positive controls (bacterial, fungal or cell culture without inhibitor) and the standards. Plates with a Z'-Factor of ≥0.4 and standards active at the highest and inactive at the lowest concentration, were accepted for further data analyses.
Statistical analyses
All statistical analyses were performed using GraphPad Prism 7 software. Results are expressed as mean ± SEM, unless otherwise stated in the designated figure legend. Comparisons of 3 or more groups of data were performed using one-way ANOVA followed by Dunnett's multiple comparison test to compare experimental values to the identified control. Comparisons of 2 sets of data used Student's t-tests. P values were calculated using GraphPad Prism 7 and presented accordingly: ****, extremely significant, p < 0.0001; ***, extremely significant, p = 0.0001-0.001; **, very significant, p = 0.001-0.01; *, significant, p = 0.01-0.05; p > 0.05 were deemed statistically insignificant.
The presented investigation considers the following Null hypotheses (H 0 ); H 01 : There is no significant growth inhibition of microbial cells treated with MitP and related analogues compared to cells treated with medium alone.
H 02 : There is no significant difference in eukaryotic cellular cytotoxicity following treatment with position-14 modified MitP (Δ14MitP) analogues compared to MitP alone.
H 03 : There is no significant difference in mast cell secretory activity following treatment with Δ14MitP analogues compared to MitP alone. Table 1 highlights the broad range of antibiotic activities of endogenous MPs and structural homologues to date. However, if indeed determined, these peptides clearly exhibit cytotoxicity towards eukaryotic cells and demonstrate mast cell stimulatory properties.
Results
Eukaryotic cytotoxicity profiles of Δ14MitP analogues
U373MG human astrocytoma cells were used to determine the cytotoxicity profiles of our newly synthesised position-14 modified MitP (Δ14MitP) analogues (Table 2 , Fig. 1 ). We have previously reported that maximum reductions in U373MG cell viability are evident following 4 h exposure to MitP and associated analogues [26, 31] . The rationale for substitution of Leu with Trp at position-14 of MitP was to minimise eukaryotic cell toxicity [38, 39] with cytotoxicity data using U373MG cells, these peptides were deemed to be inactive giving CC 50 values of > 32 mg/L and gave maximal responses (DMax) which demonstrated a reduction in cytotoxicity compared to MitP (p < 0.0001, Table 3 ). In contrast, MitP and target-selective analogues [26] , Z-Gly-RGD D Phe-MitP and Z-Gly-RGE D Phe-MitP, were confirmed to be cytotoxic in this system giving CC 50 values of ≤32 μg/mL (Table 3) . Table 1 Primary sequences of MP-related peptides and selected biological activities. Unless otherwise indicated, all peptides have an amidated carboxyl terminal. Note that Leu occupies position-14 in a majority of endogenous sequences. In many cases peptides with antibacterial activities have not been tested in eukaryotic cell systems. D-amino acids are shown in lower case. *Indicates an activity that is greatly attenuated compared with other MP analogues. Abbreviations: Adec, 2-amino-decanoamide; Gu, guanidinyl; MC, mast cell; ND, not determined. Abbreviations: Aib, 2-aminoisobutyric acid; Orn, ornithine; Z, carboxybenzyl.
Diminished mast cell secretory properties of Δ14MitP analogues
RBL-2H3 cells were used as a mucosal mast cell model and secretory events were determined by assaying the exocytosis of the lysosomal marker β-hexosaminidase. We have previously reported [23] Δ14MitP analogues demonstrated a significant decrease (p < 0.0001) in secretory response compared to MitP at these corresponding concentrations, (Fig. 2) .
Cellular penetration and mitochondrial accretion of Δ14MitP analogues
Considering the probable endosymbiotic origin of mitochondria [28] and the fact that MitP translocates eukaryotic plasma membranes to subsequently and specifically redistribute to mitochondria [26] , Δ14MitP analogues were assessed for their mitochondrial co-localization propensity. Fig. 3 further antimicrobial screening.
Primary antimicrobial screening and identification of candidate antimicrobials
Initial screening of a broad range of polycationic cell penetrating peptides (CPPs) was performed at a single peptide concentration of 32 mg/L (n = 2) and measured inhibition of growth against 5 bacteria; Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumanni, Pseudomonas aeruginosa and Staphylococcus aureus and 2 fungi: Candida albicans and Cryptococcus neoformans. The peptides highlighted in Table 2 were deemed active according to the following criteria; inhibition of bacterial or fungal growth was ≥80% and a Z-score ≥ 2. membranes [27] . Primary antimicrobial screening further highlighted the antimicrobial potential of the privileged structure that is MP. Accordingly, 6 of the 7 candidate antimicrobials were MP analogues, whereas the remaining 13 polycationic CPP were deemed to be inactive against all organisms included in this study. Inactivity was based on inhibition of bacterial or fungal growth < 80% or a Z-score of < 2.5 and was reported for the following polycationic peptides: Sequences derived from human cytochrome c (Cyt c [33] , and a sequence derived from the eye-specific ovo transcription factor of the planarian Schmidtea mediterranea (H-IVKTIKVKRRNFAEYIKKL-NH 2 ).
MIC and DMax values of candidate antibacterial agents
MICs were determined as the lowest concentration at which growth was fully inhibited and defined by an inhibition ≥80%, (Table 4) . MitP, according to the criteria stipulated in Table 4 ]MitP exhibited a mean maximal inhibitory growth response of 76.57% against P. aeruginosa (p < 0.0001, Table 4 ).
MIC values of candidate antifungal agents
MICs were determined as the lowest concentration at which growth was fully inhibited and defined by an inhibition ≥80% for C. albicans and an inhibition ≥70% for C. neoformans. activity against both C. neoformans and C. albicans, whilst LRRK2 2413−2427 was active against C. neoformans (Table 4 ). This latter peptide was also confirmed to be non-cytotoxic in HEK293 cells (Table 3 ).
Discussion
Examples of endogenous peptide antibiotics are currently numbered in their thousands [40] [41] [42] . Considering the pressing need to identify entirely new classes of antibiotic, particularly agents active against Gram-negative organisms [43] , peptides extracted from natural sources, including those isolated from animal venoms [44, 45] , are a valuable commodity. As described herein (Table 1) , wasp venoms from Antibacterial: The MIC (mg/L) was determined as the lowest concentration at which the growth was fully inhibited, defined by an inhibition ≥80%. In addition, the maximal percentage of growth inhibition is reported as DMax (maximal response), which additionally indicates any compounds with partial activity at the maximum screened concentration (32 mg/L). Antifungal: The MIC was determined as the lowest concentration at which the growth was fully inhibited, defined by an inhibition ≥80% for C. albicans and an inhibition ≥70% for C. underwent further statistical analysis to establish significant growth inhibition when compared to cells treated with medium alone, (****P < 0.0001, ***P < 0.001, one-way ANOVA followed by Dunnett's multiple comparison test).
many species contain significant amounts of a MP peptide that, following envenomation, rapidly induces dolor, rubor, calor and tumor; four classic symptoms of acute inflammation. The common privileged structure of MP peptides, mirrored in part by the mitochondriotoxic MitP, enables this genus of peptides to cross biological membranes and regulate the activities of protein targets that include heterotrimeric G proteins [3, . This localized receptor-independent activation of MC secretion, the primary response driving adverse reactions to wasp stings, is a major caveat to the therapeutic utility of most MP-related cationic sequences Thus, a major objective of this study was to introduce minor changes to the scaffold structure of MitP in order to maintain membrane translocating activity but to reduce or negate both MC secretion and eukaryotic cell toxicity.
Of particular relevance to this study, many MP peptides have antimicrobial activities (Table 1 ) and there are other pertinent examples of cationic α-helical peptide antibiotics which include the magainins and cercopins [42] . As noted by others [46] , the ability to cross or intercalate into a biological membrane is a common feature of both cationic cell penetrating peptides (CPPs) and many antibiotic peptides. Moreover, we would classify antibiotic MP analogues as bioportides, a designated class of bioactive CPPs distinct from inert delivery vectors [47, 48] . As described and presented herein (Table 4) , MitP is a broadspectrum antimicrobial and could have utility for non-medical applications such as aquaculture and domestic usage. Moreover, the extensive structure activity relationships of endogenous and synthetic MP analogues indicated that it could be possible to engineer novel analogues of MitP devoid of undesirable biological activities. For example, the synthetic MP analogue [Lys 10 , Leu 13 ]MP (mas 11) lacks the usual lytic activity of MP peptides but is a more potent activator of secretion from rodent peritoneal MCs [49] . Hence, we chose to modify the carboxyl terminal of MitP, usually occupied by the hydrophobic residue leucine, with other natural amino acids. For example, the substitution of serine into position-14 directs a polar hydroxyl group at the distal end of the hydrophobic face of [Ser 14 ]MitP when modelled as a 3.6 13 α-helix, (Fig. 4) .
A common biological activity of MP peptides is the ability to promote cell lysis or, more specifically, haemolysis [41, 42, [50] [51] [52] [53] . This disruption of biological membranes by cationic peptides has been widely proposed as a general mechanism of antibiotic activity. Both MP and HR1 (Table 1 ) may accumulate on the outer surface of biological membranes and promote membrane breakdown by the carpet mechanism [50, 54] . Accordingly, electrostatic interactions between α-helical cationic peptides and negatively charged membrane components promote peptide accumulation at the membrane surface [55, 56] . At a critical concentration sufficient peptide, bound in an orientation that is parallel to the membrane surface, "carpets" the bilayer to promote membrane disintegration by a detergent-like mechanism. Clearly, the additional Lys residues added to the privileged scaffold of MitP analogues (Fig. 4) would favour a molecular interaction with more anionic bacterial membranes compared with more zwitterionic eukaryotic plasma membranes [50, 52] . However, a variety of alternative membrane permeation mechanisms are possible [41, 42, 55, 56] that may also contribute to the molecular basis of membrane selectivity and antimicrobial activity observed amongst some MP peptides [50, 55, 57] . We anticipate that future studies will more clearly define the antimicrobial mechanism of action of MitP analogues and such data will provide guidelines for the engineering of second generation Δ14MitP analogues.
The privileged structure of MP and related sequences is readily modified either during or post synthesis and single amino acid substitutions within a tetradecapeptide helix can produce dramatic changes in biological activities [52] [53] [54] and/or membrane selectivity (Fig. 4) . Of particular relevance to this study, the substitution of Ala at position-14 in MP-X ([Ala 14 ]MP-X; Table 1 ) resulted in a higher specificity for red blood cell membranes compared with bacteria [57] . Similar substitution with the more hydrophobic amino acid 2-aminodecanoic acid ([Adec 14 ]MP-X; Table 1 ) increased bactericidal potency but reduced membrane selectivity [57] . As exemplified by the collective biological activities of Δ14MitP analogues, perturbation of the tertradecapeptide amphipathic helical structure can diminish some undesirable properties of the parent compounds whilst maintaining promising antimicrobial activities. For example, [Ser 14 ]MitP entirely lacks the capacity of MitP and target-selective analogues to promote MC degranulation and is essentially non-toxic when applied to eukaryotic cells, (Figs. 1 and 2, Table 3 ). Our studies also confirmed (Fig. 3d) ]MitP does not prevent mitochondrial membrane accumulation but negates the activation of the voltage-dependent anion channel (VDAC) which leads to the release of apoptogenic cytochrome c from mitochondria [26] . This observation also alludes to the possibility of using MitP analogues to target intracellular microorganisms without detriment to the host cell. In contrast, [Trp 14 ]MitP displays significant cytotoxicty in eukaryotic cell systems ( Fig. 1) and it was therefore initially predicted that [Trp 14 ]MitP, as is the case with MitP, was inducing late intrinsic apoptotic events through cooperation with the permeability transition pore-associated protein VDAC, with a consequential release of cytochrome c and activation of the caspase cascade [26] . However, live confocal cell imaging analysis (Fig. 3D) clearly demonstrates that [Trp 14 ]MitP does not accrete within mitochondrial membranes and therefore suggests, particularly within a 4 h incubation period, a necrotic mechanism of cell death, such as induction of nonspecific perturbations of the plasma membrane as is the case with high concentrations (> 20 μM) of many MP analogues [10, 23, 31, 50] . If general membrane perturbation is a common mechanism of action of antimicrobial MitP analogues, then structural or biochemical differences between mitochondrial, bacterial and fungal membranes might provide some explanation for the distinct activity profiles of peptides characterised and described herein. There is superficial ultrastructural similarity between the double membrane systems of the eukaryotic mitochondrion and Gram-negative bacteria including A. baumannii. Mitochondrial membranes are composed of all of the major classes of phospholipids that constitute eukaryotic plasma membranes, with the addition of small quantities of cardiolipin [59] . Moreover, the mitochondrial outer membrane, the presumed initial site of accretion of some but not all MitP analogues is a relatively simple phospholipid bilayer enriched in porin proteins. Conversely, the bacterial cell envelope is a more variable and complex multi-layered structure [60] . The outer membrane (OM), a distinguishing feature of Gram-negative bacteria, is not a phospholipid bilayer but is predominantly composed of glycolipids, principally the highly immunogenic lipopolysaccharide. A majority of proteins located within the OM comprise either lipoproteins or others of a ß-barrel tertiary structure including porins [60, 61] . It is noteworthy that, when screening a total of 15 antimicrobial peptides, melittin, indolicidin and MP were identified as being effective against both colistin-susceptible and colistin-resistant A. baumannii [8] . The potential importance of the further development of Δ14MitP analogues to combat A. baumannii infections, particularly in immunosuppressed patients, is amplified by the identification of colistin-resistant A. baumannii clinical isolates at the start of the new millennium [62] . Our data provide hope that other Δ14MitP analogues might display enhanced activities against A, baumannii and other pathogenic bacteria whilst maintaining the desirable properties of [Ser 14 ]MitP in eukaryotic cell systems.
In common with the cell envelopes of bacteria, the composition of fungal cell walls is also highly variable, structurally unique and primarily composed of glycoproteins and polysaccharides [63] . There is no double membrane system but, in order to access the plasma membrane of fungi, antimicrobial peptides must cross a dynamic cell wall that functions to maintain the structural integrity and metabolic function of the eukaryotic cell [63] . Indeed, there are major compositional differences in the various layers of the cell wall of Candida and Cryptococcus species, the latter being surrounded by a relatively thick polysaccharide capsule that can inhibit the function of phagocytes [64] . We were, therefore, surprised to observe that a larger variety of screened peptides, including all MitP analogues and an unrelated cationic sequences from LRRK2, were active against C. albicans and/or C. neoformans. The Δ14MitP analogues are particularly promising and relatively selective antifungal agents. These findings also suggest that cationic CPP may induce fungal cell death by a common mode of action that is distinct from that of agents which target sterols or target cell wall synthesis [65] . Since a majority of C. neoformans infections take place in the lungs of immunocompromised patients [66] , there is clearly scope to develop non-secretory analogues of MitP for topical application perhaps combined with anti-HIV medications.
Conclusions
Collectively, our data indicate that MitP is a viable template for the development of unique antibiotic peptides. It is now clear that relatively minor changes to the core tetradecaptide sequence of either MP or MitP can lead to distinct changes in activity. Furthermore, our studies with Δ14MitP analogues have illustrated an effective route towards the development of antimicrobials that lack detrimental activities against eukaryotic cells. Molecular modelling, using computational algorithms to define quantitative structure-activity relationships (QSAR) [67, 68] , could be a useful strategy to further engineer MitP peptides. The oral bioavailability of such peptides could be addressed by the incorporation of D-amino acids [56] or unnatural moieties [57] at labile sites such as between position I 1 and N 2 [8] . Many other structural modifications to the privileged scaffold are also feasible [48] , and more sophisticated strategies could be utilised to selectively deliver antibiotic peptides to the sites of human infection [48] . Of particular relevance to this study, a polymeric delivery system has been developed [69] to direct MitP to human tumours. Self-assembled nanoparticles of cationic antibiotic peptides, designed to disintegrate in contact with an anionic bacterial cell surface, might also be adapted to deliver MitP analogues in vivo [70] . Finally, Δ14MitP analogues could be combined with other clinically useful antibiotics to improve efficacy and combat multipleantibiotic-resistant strains of bacteria and fungi [71] .
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